The study conducted at Kaiser Permanente in San Francisco involved more than 600 high-risk individuals, most of whom were men who have sex with men.
These individuals were healthy at the time of enrolment and were put on a daily regimen of a blue pill called Truvada as a pre-exposure prophylaxis (PrEP).
In this study, 100 percent of the participants remained HIV-free. That’s right, not a single person in the study, published in Clinical Infectious Diseases, became infected while on the drug during the study period that included 2.5 years of observation.
Read more at washingtonpost.com
